RxDoctor Payments DataLook up a doctor →

Barry Hendin, MD

Neurology · Phoenix, AZNPI 1447239231

Payments from drug & device makers

$4,353,687in general payments, 2019–2025

Across 2,824 payments — averaging $1541.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.5M
  • EMD Serono, Inc.$696K
  • Biogen$454K
  • Genentech, Inc.$367K
  • Genentech USA, Inc.$233K
  • E.r. Squibb & Sons, L.L.C.$154K
  • plus $941K from 49 others
$48,937in research payments, 2019–2025

Across 17 payments — averaging $2878.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$41K
  • F. Hoffmann-la Roche AG$6K
  • Novartis Pharma AG$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,353,687 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$50,886
Medicare patients
14
Services billed
1,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →